Matches in Nanopublications for { ?s ?p "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_provenance.
- NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_provenance.
- NP1042709.RAiu7fwxcu98ndn4zdbyTmcIBRahDOYnP6Xw4GEaxtrwQ130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1042709.RAiu7fwxcu98ndn4zdbyTmcIBRahDOYnP6Xw4GEaxtrwQ130_provenance.
- NP519351.RAOoEI0tNYkGhiFRdzY5ukvsiZQdGx_Uao-elxVMwRfQo130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519351.RAOoEI0tNYkGhiFRdzY5ukvsiZQdGx_Uao-elxVMwRfQo130_provenance.
- NP518946.RA_dNVMGB1UD_7KvTZ79gAprOkKBUra9_aeuZ4zrK7SgI130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP518946.RA_dNVMGB1UD_7KvTZ79gAprOkKBUra9_aeuZ4zrK7SgI130_provenance.
- NP1042711.RAGxcB23KxPnKeENfBY_R6M976zq7PCj24Q86najYXn8s130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1042711.RAGxcB23KxPnKeENfBY_R6M976zq7PCj24Q86najYXn8s130_provenance.
- NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- NP1042710.RA0ZVCVYmULDLFrXnldx79wHTB2m7Wt3Spj5ubmO1HI7k130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1042710.RA0ZVCVYmULDLFrXnldx79wHTB2m7Wt3Spj5ubmO1HI7k130_provenance.